Patient-reported symptom monitoring for people with head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with localized head and neck squamous cell carcinoma who are receiving curative radiotherapy or radiochemotherapy will use a medical telemonitoring solution to report symptoms remotely during treatment and for follow-up. Clinicians receive these patient-reported outcomes and can provide timely supportive care, including nutritional interventions, when problems are detected. The primary outcome is the proportion of patients who lose at least 5% of body weight between before radiotherapy and three months after treatment. Participation requires access to a smartphone or the internet and follow-up at one of the participating cancer centers in France.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged over 18 and under 75 years WHO score \< 2,

  * Treated for localised heand and neck cancer of the squamous cell carcinoma type for which curative treatment has been chosen and receiving radiotherapy or radio-chemotherapy exclusively or as an adjuvant with the aim of cure
  * Having signed the informed consent form,
  * Affiliated with or beneficiary of a social protection scheme,
  * Access to a smartphone or the internet,

Exclusion Criteria:

* History of other neoplastic disease less than 2 years ago or progressive disease,
* History of ENT radiotherapy,
* Pregnant or breastfeeding women,
* Protected adults (under guardianship, curatorship or judicial protection),
* Patients participating in a therapeutic study,
* Patients unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological or geographical issues, etc.), patients with blindness preventing the use of the medical telemonitoring solution in oncology.

Where it's running

• Centre Henri Becquerel
  Rouen, France Recruiting
• Institut de Cancérologie de Lorraine
  Vandœuvre-lès-Nancy, France Not yet recruiting

Study contacts

• Principal investigator: Sebastien Thureau, MD,PhD — Centre Henri Becquerel
• Study coordinator: Sebastien Thureau, MD,PhD
• Email: sebastien.thureau@chb.unicancer.fr
• Phone: +33232082992

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Triple-drug neoadjuvant therapy for EGFR-positive locally advanced head and neck cancer

  This trial tests a three-drug neoadjuvant regimen (Becotatug Vedotin, Pucotenlimab, and Cisplatin) in adults with EGFR-positive, locally advanced head and neck cancer to see if it can shrink tumors before surgery or chemoradiotherapy.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07814287

• CCR2 PET Imaging for Head and Neck Squamous Cell Carcinoma

  This trial tests whether Cu-64 DOTA-ECL1i PET/CT can reliably detect HNSCC in adults, including those with new locally advanced disease or suspected/confirmed recurrent/metastatic cancer.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07659678

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

• Re-irradiation with chidamide for recurrent head and neck squamous cell carcinoma

  This trial will test whether adding the drug chidamide to repeat radiation is safe and tolerable for adults whose head and neck squamous cell carcinoma has returned after prior radiotherapy.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07545967

• Dose-finding of EXS74539 (REC-4539) in select solid tumors

  This study will try different doses of the experimental drug EXS74539 in adults with select solid tumors to find a safe and tolerable dose.

  Recruiting at 3 sites Phase 1 Exscientia AI Limited · Los Angeles, California and 2 other locations · NCT07517198

• Ficerafusp alfa plus pembrolizumab before surgery for resectable head and neck squamous cell carcinoma

  This trial will test whether giving ficerafusp alfa together with pembrolizumab before surgery helps people with PD‑L1–positive, resectable, high‑risk head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07465276

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.